The company intends to use the funds for pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

19 Blackstone St.
Cambridge, MA 02139
USA

Phone

(857) 706-1427

Website

www.vedantabio.com

Email Address

[email protected]

Overview

Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases.

Profile

Social Media

Vedanta Biosciences Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bernat Olle

Chief Financial Officer

Mark Mullikin

Chief Medical Officer

Jeffrey Silber

Chief Operating Officer

Daniel Couto

VP - Bus. Development

Taylor Feehley

VP - Finance

Maggie McGuigan

VP - Human Resources

Jack Kyte

VP - Manufacturing

Kris Ireland

VP - Operations

Lorraine Hughes

VP - Operations

Debra Winslow

VP - Regulatory Affairs

Anne Kuan

VP - Regulatory Affairs

Thomas O'Brien

Browse more venture capital transactions:

Prev: 4/25/2023: Ox venture capital transaction
Next: 4/25/2023: Huntress venture capital transaction

Share this article

About Database of VC Transactions

We do our best to record tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary